Navigation Links
NW Bio's International Phase III GBM Brain Trial Is Subject Of BBC TV Report In The UK
Date:12/30/2013

address the variability. As described in the BBC report, DCVax-L is a personalized treatment made from the patient's own immune cells (dendritic cells) and biomarkers from the patient's own tumor. 

After reviewing and evaluating the DCVax-L technology and the current international Phase III clinical trial of DCVax-L for GBM, the National Health System (NIHR) "adopted" this trial as a nationwide priority in the UK, singling it out for additional resources and attention, as previously reported by the Company.  

"We appreciate the BBC highlighting the importance of the emerging category of immune therapies for cancer and profiling our advanced clinical trial, thereby helping to bring this information to the attention of patients" commented Linda Powers, CEO of NW Bio.  "Patients are urgently seeking new and better treatment options, but often have difficulty finding out about innovative new technologies such as DCVax-L.  The BBC's report will help many patients become aware of these potential new treatment options."

About Northwest Biotherapeutics

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio's proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead product, DCVax-L, is currently in a 312-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  The Company's second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.  The Company has also conducted a Phase I/II
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. Neurocrine Biosciences Reports First Quarter 2012 Results
7. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
8. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
9. BioSurplus Announces Launch of Depot Service for Agilent and AKTA HPLCs
10. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
11. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Phase I ... the US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology ... today announces that it has begun a Phase I, ... inhibitor, KVD001, for the treatment of DME. The study,s ... Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical School ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... March 15 Sequenom, Inc. (Nasdaq: SQNM ) today reported its financial results for the fourth quarter and year ended December 31, 2009 . , ... , , ... ...   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ...
... March 15 International Merchant Advisors, ... today that the company has completed the purchase of ... Inc. in an all stock transaction.  Organic Science, Inc. will ... this business segment, and is focused on the ...
Cached Medicine Technology:Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 2Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 3Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 4Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 5Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 6Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 7Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 8Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 9Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 10Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 11Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 12Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 13Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 14Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 15Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 16International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 2International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 3
(Date:8/20/2014)... Rockville Centre, NY (PRWEB) August 20, 2014 ... Martinotti and filed on August 7 in the multicounty ... New Jersey (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; ... in the MCL have been dismissed without prejudice. The ... “in the process of being resolved.” The Rottenstein Law ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... One Call Alert expands its line of personal ... fully-mobile wearable device that connects customers to the help they ... a day, 365 days a year. , ResCube can go ... operates on the T-Mobile nationwide network like a cell phone, ... , Like with the other One Call Alert systems, ResCube ...
(Date:8/20/2014)... Auckland suggest that both major forms of diabetes are the ... today in the FASEB Journal (20 August), provide ... are both caused by the formation of toxic clumps of ... on 20 years, work in New Zealand, suggest that type-1 ... reversed by medicines that stop amylin forming these toxic clumps. ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... May 21, 2012. West Orange, NJ. Scientists at ... studies in multiple sclerosis at the Hilton San Diego ... John DeLuca, Nancy Chiaravalloti and Yael Goverover are addressing ... Multiple Sclerosis Centers (CMSC) and the Americas Committee for ...
... peers and primary care office staff can help patients improve ... new drug, a new study found. Barbara J. Turner, M.D., ... senior author. The randomized, controlled trial examined whether six ... care office staff could benefit African-American patients who had ...
... 21 (HealthDay News) -- Heart damage can be present in obese ... preliminary study found. Obesity is a risk factor for heart ... to their hearts. In the new study, researchers examined the ... overweight and 32 obese -- with no symptoms of heart disease. ...
... General Hospital (MGH) surgeons have developed a new technique ... In the May Annals of Otology, Rhinology ... which uses cryopreserved aortas from deceased donors to replace ... permanent tracheotomy and maintain voice and swallowing function with ...
... May 21 (HealthDay News) -- Having so-called intensivist physicians on ... death rates in ICUs that do not have similar coverage ... An intensivist is a doctor who specializes in the care ... or co-manage patients during the day are referred to as ...
... Almost a century after telephone pioneer Alexander Graham ... vapor sensors ― "electronic noses" ― are being developed ... and other futuristic uses. A new episode in ... series takes viewers on a behind-the-science tour of ...
Cached Medicine News:Health News:Kessler Foundation scientists present cognitive research findings at MS dual symposium 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Obese Teens Can Have Heart Damage Without Showing Signs 2Health News:Donor aortic graft improves reconstruction after partial laryngectomy 2Health News:Night Staffing With Critical Care Docs May Lower ICU Death Rates 2
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
Medicine Products: